Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.
Analysis of hepatitis B virus (HBV) kinetics with mathematical models may disclose new aspects of HBV infection and host response mechanisms. To determine the kinetics of virion decay from the blood of patients in different phases of chronic infection, we applied mathematical modeling to real-time polymerase chain reaction assays, which enable quantification of viremia and intrahepatic HBV productivity by measuring both copy number and activity of covalently closed circular DNA (relaxed circular DNA/covalently closed circular DNA) in the liver of 80 untreated chronically active HBV carriers (38 hepatitis B e antigen [HBeAg]-positive and 42 HBeAg-negative individuals). We found that the half-life of circulating virions is very fast (median 46 and 2.5 minutes in HBeAg-positive and HBeAg-negative individuals, respectively) and strongly related to viremia, with clearance rates significantly accelerating as viral loads decrease. To investigate whether immune components can influence the kinetics of virion decay, we analyzed viral dynamics in immunodeficient urokinase-type plasminogen activator chimera mice. Virion half-life in mice (range, 44 minutes to >4 hours) was comparable to estimates determined in high viremic carriers, implying that clearance rates in these patients are mostly determined by common nonspecific mechanisms. Notably, the lack of correlation between virion half-life and viremia in mice indicated that immune components significantly accelerate virion clearance rates in individuals with low titers.


CONCLUSIONS
Our analyses suggest that both host defense mechanisms and levels of circulating virions affect the kinetics of HBV decay assessed in the serum of chronic carriers. Identification of the factors affecting clearance rates will be important for future antiviral drug developments and it may give insights into the mechanisms involved in clearance of other chronic infections, such as human immunodeficiency virus and hepatitis C virus.
Dandri
Maura
M
Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. m.dandri@uke.uni-hamburg.de
Murray
John M
JM
Lutgehetmann
Marc
M
Volz
Tassilo
T
Lohse
Ansgar W
AW
Petersen
Joerg
J
D000328:Adult; D000818:Animals; D001706:Biopsy; D002678:Chimera / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D018628:Gene Dosage; D006207:Half-Life; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000503:physiopathology; D022781:Hepatocytes / Q000473:pathology / Q000821:virology; D006801:Humans; D008099:Liver / Q000473:pathology / Q000821:virology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D008875:Middle Aged; D008954:Models, Biological; D008962:Models, Theoretical; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics; D019562:Viral Load; D014766:Viremia / Q000503:physiopathology*; D014771:Virion / Q000235:genetics / Q000502:physiology*
D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D014568:Urokinase-Type Plasminogen Activator